Cargando…

The Burden of Systemic Lupus Erythematosus in Germany: Incidence, Prevalence, and Healthcare Resource Utilization

INTRODUCTION: We evaluated incidence, prevalence, costs, and healthcare utilization associated with systemic lupus erythematosus (SLE) in patients in Germany. METHODS: Adult patients with SLE were identified from the German Betriebskrankenkassen (BKK) health insurance fund database between 2009 and...

Descripción completa

Detalles Bibliográficos
Autores principales: Schwarting, Andreas, Friedel, Heiko, Garal-Pantaler, Elena, Pignot, Marc, Wang, Xia, Nab, Henk, Desta, Barnabas, Hammond, Edward R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7991067/
https://www.ncbi.nlm.nih.gov/pubmed/33544369
http://dx.doi.org/10.1007/s40744-021-00277-0
_version_ 1783669180248096768
author Schwarting, Andreas
Friedel, Heiko
Garal-Pantaler, Elena
Pignot, Marc
Wang, Xia
Nab, Henk
Desta, Barnabas
Hammond, Edward R.
author_facet Schwarting, Andreas
Friedel, Heiko
Garal-Pantaler, Elena
Pignot, Marc
Wang, Xia
Nab, Henk
Desta, Barnabas
Hammond, Edward R.
author_sort Schwarting, Andreas
collection PubMed
description INTRODUCTION: We evaluated incidence, prevalence, costs, and healthcare utilization associated with systemic lupus erythematosus (SLE) in patients in Germany. METHODS: Adult patients with SLE were identified from the German Betriebskrankenkassen (BKK) health insurance fund database between 2009 and 2014. SLE incidence and prevalence were calculated for each year and extrapolated (age and sex adjusted) to the German population. The 2009 SLE population was followed through 2014. Healthcare utilization and costs for patients with SLE were calculated and compared with controls matched by age, sex, and baseline Charlson Comorbidity Index scores. RESULTS: This analysis included 1160 patients with SLE. Estimated SLE incidence between 2009 and 2014 ranged from 4.59 to 6.89 per 100,000 persons and prevalence ranged from 37.32 to 47.36 per 100,000. SLE incidence in Germany in 2014 was 8.82 per 100,000 persons; prevalence was 55.80 (corrected for right-censored data). At baseline, 12.8, 41.7, and 45.5% of patients were categorized as having mild, moderate, and severe SLE, respectively. Patients with SLE had greater mean (standard deviation [SD]) annual medical costs compared with matched controls 1 year after index diagnosis (€6895 [14,424] vs. €3692 [3994]; P < 0.0001) and in subsequent years. Patients with moderate or severe SLE had significantly more hospitalizations, outpatient visits, and prescription medication use compared with matched controls. Mean annual costs for 5 years ranged from €1890 to 3010, €4867 to 5876, and €8396 to 10,001 for patients with mild, moderate, and severe SLE, respectively. CONCLUSIONS: SLE incidence in Germany increased 1.4-fold over 5 years. Patients with SLE have higher healthcare costs, and costs increase with baseline severity. Early and effective treatments may delay progression and reduce the burden of SLE. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40744-021-00277-0.
format Online
Article
Text
id pubmed-7991067
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-79910672021-04-16 The Burden of Systemic Lupus Erythematosus in Germany: Incidence, Prevalence, and Healthcare Resource Utilization Schwarting, Andreas Friedel, Heiko Garal-Pantaler, Elena Pignot, Marc Wang, Xia Nab, Henk Desta, Barnabas Hammond, Edward R. Rheumatol Ther Original Research INTRODUCTION: We evaluated incidence, prevalence, costs, and healthcare utilization associated with systemic lupus erythematosus (SLE) in patients in Germany. METHODS: Adult patients with SLE were identified from the German Betriebskrankenkassen (BKK) health insurance fund database between 2009 and 2014. SLE incidence and prevalence were calculated for each year and extrapolated (age and sex adjusted) to the German population. The 2009 SLE population was followed through 2014. Healthcare utilization and costs for patients with SLE were calculated and compared with controls matched by age, sex, and baseline Charlson Comorbidity Index scores. RESULTS: This analysis included 1160 patients with SLE. Estimated SLE incidence between 2009 and 2014 ranged from 4.59 to 6.89 per 100,000 persons and prevalence ranged from 37.32 to 47.36 per 100,000. SLE incidence in Germany in 2014 was 8.82 per 100,000 persons; prevalence was 55.80 (corrected for right-censored data). At baseline, 12.8, 41.7, and 45.5% of patients were categorized as having mild, moderate, and severe SLE, respectively. Patients with SLE had greater mean (standard deviation [SD]) annual medical costs compared with matched controls 1 year after index diagnosis (€6895 [14,424] vs. €3692 [3994]; P < 0.0001) and in subsequent years. Patients with moderate or severe SLE had significantly more hospitalizations, outpatient visits, and prescription medication use compared with matched controls. Mean annual costs for 5 years ranged from €1890 to 3010, €4867 to 5876, and €8396 to 10,001 for patients with mild, moderate, and severe SLE, respectively. CONCLUSIONS: SLE incidence in Germany increased 1.4-fold over 5 years. Patients with SLE have higher healthcare costs, and costs increase with baseline severity. Early and effective treatments may delay progression and reduce the burden of SLE. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40744-021-00277-0. Springer Healthcare 2021-02-05 /pmc/articles/PMC7991067/ /pubmed/33544369 http://dx.doi.org/10.1007/s40744-021-00277-0 Text en © The Author(s) 2021 Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Original Research
Schwarting, Andreas
Friedel, Heiko
Garal-Pantaler, Elena
Pignot, Marc
Wang, Xia
Nab, Henk
Desta, Barnabas
Hammond, Edward R.
The Burden of Systemic Lupus Erythematosus in Germany: Incidence, Prevalence, and Healthcare Resource Utilization
title The Burden of Systemic Lupus Erythematosus in Germany: Incidence, Prevalence, and Healthcare Resource Utilization
title_full The Burden of Systemic Lupus Erythematosus in Germany: Incidence, Prevalence, and Healthcare Resource Utilization
title_fullStr The Burden of Systemic Lupus Erythematosus in Germany: Incidence, Prevalence, and Healthcare Resource Utilization
title_full_unstemmed The Burden of Systemic Lupus Erythematosus in Germany: Incidence, Prevalence, and Healthcare Resource Utilization
title_short The Burden of Systemic Lupus Erythematosus in Germany: Incidence, Prevalence, and Healthcare Resource Utilization
title_sort burden of systemic lupus erythematosus in germany: incidence, prevalence, and healthcare resource utilization
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7991067/
https://www.ncbi.nlm.nih.gov/pubmed/33544369
http://dx.doi.org/10.1007/s40744-021-00277-0
work_keys_str_mv AT schwartingandreas theburdenofsystemiclupuserythematosusingermanyincidenceprevalenceandhealthcareresourceutilization
AT friedelheiko theburdenofsystemiclupuserythematosusingermanyincidenceprevalenceandhealthcareresourceutilization
AT garalpantalerelena theburdenofsystemiclupuserythematosusingermanyincidenceprevalenceandhealthcareresourceutilization
AT pignotmarc theburdenofsystemiclupuserythematosusingermanyincidenceprevalenceandhealthcareresourceutilization
AT wangxia theburdenofsystemiclupuserythematosusingermanyincidenceprevalenceandhealthcareresourceutilization
AT nabhenk theburdenofsystemiclupuserythematosusingermanyincidenceprevalenceandhealthcareresourceutilization
AT destabarnabas theburdenofsystemiclupuserythematosusingermanyincidenceprevalenceandhealthcareresourceutilization
AT hammondedwardr theburdenofsystemiclupuserythematosusingermanyincidenceprevalenceandhealthcareresourceutilization
AT schwartingandreas burdenofsystemiclupuserythematosusingermanyincidenceprevalenceandhealthcareresourceutilization
AT friedelheiko burdenofsystemiclupuserythematosusingermanyincidenceprevalenceandhealthcareresourceutilization
AT garalpantalerelena burdenofsystemiclupuserythematosusingermanyincidenceprevalenceandhealthcareresourceutilization
AT pignotmarc burdenofsystemiclupuserythematosusingermanyincidenceprevalenceandhealthcareresourceutilization
AT wangxia burdenofsystemiclupuserythematosusingermanyincidenceprevalenceandhealthcareresourceutilization
AT nabhenk burdenofsystemiclupuserythematosusingermanyincidenceprevalenceandhealthcareresourceutilization
AT destabarnabas burdenofsystemiclupuserythematosusingermanyincidenceprevalenceandhealthcareresourceutilization
AT hammondedwardr burdenofsystemiclupuserythematosusingermanyincidenceprevalenceandhealthcareresourceutilization